Cell-based therapies are being developed for various neurodegenerative diseases that
affect the central nervous system (CNS). Concomitantly, the roles of individual cell types in …

The specific loss of midbrain dopamine neurons (mDANs) causes major motor dysfunction
in Parkinson's disease, which makes cell replacement a promising therapeutic approach …

Parkinson's disease (PD) is the second most common neurodegenerative disorder after
Alzheimer's disease, affecting 1%–2% of the population over the age of 65. As the …

Human embryonic stem cell (hESC)-derived midbrain dopaminergic (mDA) cell
transplantation is a promising therapeutic strategy for Parkinson's disease (PD). Here, we …

Parkinson's disease is a neurodegenerative condition characterized by motor impairments
caused by the selective loss of dopaminergic neurons in the substantia nigra. Levodopa is …

Although striatal delivery of three critical genes for dopamine synthesis by viruses is a
potential clinical approach for treating Parkinson's disease (PD), the approach makes it …

Transplantation of human induced pluripotent stem cell-derived dopaminergic (iPSC-DA)
neurons is a promising therapeutic strategy for Parkinson's disease (PD). To assess optimal …

Background: Platelet-rich plasma (PRP), a blood-based product containing platelets and
growth factors, is being utilized to treat numerous non-hemostatic disorders. Studies have …

Parkinson's disease (PD) is a relentlessly progressive and currently incurable
neurodegenerative disease with significant unmet medical needs. Since PD stems from the …

α-synuclein (α-syn) is an intrinsically disordered protein abundant in the central nervous
system. Physiologically, the protein regulates vesicle trafficking and neurotransmitter release …